Urology News and Research

Latest Urology News and Research

$Ambit, Astellas commence quizartinib Phase 2b trial in relapsed/refractory AML$

Ambit, Astellas commence quizartinib Phase 2b trial in relapsed/refractory AML

Astellas Pharma Inc. and Ambit Biosciences Corporation today announced the initiation of a Phase 2b open-label clinical trial of quizartinib as monotherapy in patients with relapsed and refractory acute myeloid leukemia (AML) with FLT3-ITD mutations.

5 Jun 2012

Positive results from Auxilium’s XIAFLEX phase III studies on Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive top-line results from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).

4 Jun 2012

Study identifies several proteins as new therapeutic targets and biomarkers for kidney cancer

Using blood, urine and tissue analysis of a unique mouse model, a team led by UC Davis researchers has identified several proteins as diagnostic biomarkers and potential therapeutic targets for kidney cancer. Subject to follow-up validation testing, inhibition of these proteins and several related pathways holds promise as a form of therapy to slow the growth of kidney tumors.

2 Jun 2012

First U.S.-based study to assess per-patient annual economic costs of fecal incontinence

Care for patients with fecal incontinence costs $4,110 per person for both medical and non-medical costs like loss of productivity, according to new research from the University of Michigan.

2 Jun 2012

European Multidisciplinary Meeting on Urological Cancers to be held in Barcelona

With the goal to deliver an in-depth review of the latest multi-modal management strategies for urological cancers, the 4th European Multidisciplinary Meeting on Urological Cancers (EMUC) will be held from 16 to 18 November 2012 in Barcelona, Spain.

2 Jun 2012

Taiho to initiate TAS-102 Phase III trial in colorectal cancer

Taiho Pharmaceutical Co., Ltd. announced on May 31 that a global Phase III clinical trial (RECOURSE) for the novel combination antimetabolite TAS-102 will start in June this year.

31 May 2012

Surprising life-quality benefit from early prostate cancer treatment

Treatment of early-stage prostate cancer may also improve quality of life if patients have previously suffered from obstructive urinary symptoms before undergoing treatment, shows US research.

30 May 2012

Dehydration: how much should we drink per day?

As the northern hemisphere approaches the summer months, many of us begin to think about drinking more to prevent dehydration. But exactly how much should we be drinking a day? Does the amount vary depending on what we are drinking? And what happens if we don’t drink enough fluid?

30 May 2012

Endo, Watson reach agreement to resolve two LIDODERM patent infringement lawsuits

Endo announced today that it has reached an agreement with Watson Pharmaceuticals (Watson) resolving two patent infringement lawsuits related to LIDODERM.

30 May 2012

Watson, Endo and Teikoku Seiyaku enter settlement agreement to resolve Lidoderm patent litigation

Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has entered into an agreement with Endo Pharmaceuticals Inc. and Teikoku Seiyaku Co., Ltd to settle all outstanding patent litigation related to Watson's generic version of Lidoderm.

29 May 2012

UCLA geneticists identify mutation responsible for IMAGe syndrome

UCLA geneticists have identified the mutation responsible for IMAGe syndrome, a rare disorder that stunts infants' growth. The twist? The mutation occurs on the same gene that causes Beckwith-Wiedemann syndrome, which makes cells grow too fast, leading to very large children.

28 May 2012

Auxilium, FCB I file suit against Watson over generic Testim

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Testosterone Gel, 1%. Watson's 1% testosterone gel product is a generic version of Auxilium Pharmaceuticals, Inc.'s Testim 1%.

25 May 2012

PSA test benefits are questionable, yet physicians struggle to stop them

Recent recommendations from the U.S. Preventive Services Task Force (USPSTF) advising elimination of routine prostate-specific antigen (PSA) screening for prostate cancer in healthy men are likely to encounter serious pushback from primary care physicians, according to results of a survey by Johns Hopkins investigators.

24 May 2012

NYU Langone surgeons perform robotic-assisted partial nephrectomy in New York

A team of urological surgeons from NYU Langone Medical Center performed a robotic-assisted partial nephrectomy in New York and beamed the procedure from New York via high definition satellite to more than 400 participants attending the American Urological Association's (AUA) 2012 Annual Meeting in Atlanta earlier this week.

24 May 2012

Number of Americans with kidney stones nearly doubled since 1994

The number of Americans suffering from kidney stones between 2007 and 2010 nearly doubled since 1994, according to a study by researchers at the University of California, Los Angeles (UCLA) and RAND.

24 May 2012

CMS sticks with Medicare coverage of PSA test

The federal government is not changing coverage plans "at this time." Meanwhile, a number of urologists and other medical specialists raise concerns that new recommendations against prostate cancer screening will hurt men's health.

24 May 2012

RARP more costly than RRP in treating prostate cancer

In one of the most comprehensive analyses to date of the cost of robotic-assisted, laparoscopic surgery for prostate cancer, researchers at UPMC found that this now-dominant surgical approach is significantly more costly than standard open surgery, despite little scientific evidence of long-term improved patient outcomes.

24 May 2012

Study shows how chromosomal mutation likely contributes to early development of prostate cancer

Up to half of all prostate cancer cells have a chromosomal rearrangement that results in a new "fusion" gene and formation of its unique protein -- but no one has known how that alteration promotes cancer growth. Now, Weill Cornell Medical College researchers have found that in these cancer cells, the 3-D architecture of DNA, wrapped up in a little ball known as a chromatin, is warped in such a way that a switch has been thrown on thousands of genes, turning them on or off to promote abnormal, unchecked growth. Researchers also found that new chromosomal translocations form, further destabilizing the genome.

23 May 2012

MDxHealth announces availability of ConfirmMDx for Prostate Cancer test

MDxHealth SA, a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced it has presented data demonstrating that its epigenetic ConfirmMDx for Prostate Cancer test can aid urologists in identifying patients who may avoid a repeat prostate biopsy.

23 May 2012

Cooper Green installs Medsphere's OpenVista EHR

MedsphereSystems Corporation and Cooper Green Mercy Hospital today announced that Cooper Green has gone live on Medsphere's OpenVista open source electronic health record (EHR).

22 May 2012